Recent Articles

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

| September 28, 2017 | 0 Comments

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.See Original Article

Continue Reading

Low-Tech Outreach Methods Improve Colorectal Cancer Screening

| September 26, 2017 | 0 Comments

Low-Tech Outreach Methods Improve Colorectal Cancer Screening Proactive, low-tech outreach approaches can help increase the number of people who get screened for colorectal cancer with a colonoscopy or home stool test and complete the appropriate follow-up.See Original Article

Continue Reading

FDA Expands Approval of Fulvestrant for Advanced Breast Cancer

| September 22, 2017 | 0 Comments

FDA Expands Approval of Fulvestrant for Advanced Breast Cancer FDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy. See Original Article

Continue Reading

Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan

| September 20, 2017 | 0 Comments

Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan NCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.See Original Article

Continue Reading

Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar

| September 19, 2017 | 0 Comments

Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar On October 5, 2017, Dr. John M. Carethers will deliver the second CURE Distinguished Scholars Seminar. Dr. Carethers will present highlights from his research in hereditary colon cancer, tumor progression, and colorectal cancer disparities. See Original Article

Continue Reading

Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer

| September 19, 2017 | 0 Comments

Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.See Original Article

Continue Reading

FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic Leukemia

| September 18, 2017 | 0 Comments

FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic Leukemia FDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.See Original Article

Continue Reading

FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer

| September 14, 2017 | 0 Comments

FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer FDA has granted regular approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy.See Original Article

Continue Reading

Brain Cancer’s Cholesterol Addiction May Offer New Treatment Strategy

| September 12, 2017 | 0 Comments

Brain Cancer’s Cholesterol Addiction May Offer New Treatment Strategy Brain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival.See Original Article FDA Approves New Use for Lenalidomide in Multiple Myeloma […]

Continue Reading

Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of Death

| September 12, 2017 | 0 Comments

Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of Death In a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.See Original Article

Continue Reading